ALZpath Enhances Strategic Partnership with Alamar Biosciences for Alzheimer's Diagnostics

ALZpath Expands Strategic Collaboration with Alamar Biosciences

ALZpath, Inc., a pioneer in diagnostic solutions utilizing blood tests for Alzheimer's disease, has recently announced the expansion of its strategic partnership with Alamar Biosciences. This broadened collaboration signifies a significant step forward in the realm of clinical diagnostics, particularly concerning blood-based testing for Alzheimer's disease.

The updated agreement officially grants Alamar commercial rights to employ ALZpath's proprietary pTau217 antibody within blood diagnostic tests meant for clinical application. This initiative aims to enhance the reach and adoption of high-performance blood biomarkers across both research and clinical environments.

Initially, in February 2024, ALZpath and Alamar Biosciences established a foundational strategic agreement. This earlier collaboration focused on integrating the pTau217 antibody into Alamar's research use-only assays, specifically NULISAqpcr™ and NULISAseq™. With the newly expanded agreement, both Alamar and its collaborators can potentially develop in vitro diagnostic (IVD) assays that leverage this crucial antibody, thereby increasing access to meaningful blood-based testing for Alzheimer's disease.

Mike Banville, the CEO of ALZpath, emphasized the importance of this partnership, stating, "Expanding our collaboration with Alamar marks another significant milestone in making blood-based tests for Alzheimer's disease more accessible to clinicians and patients alike." He further added, "As the global adoption of pTau217 accelerates, our focus remains on enabling our partners to deliver clinically validated diagnostic solutions which yield earlier results and thus, improve patient care."

This announcement was made during the recent Annual Meeting of the Association for Diagnostics Laboratory Medicine (ADLM), where the rapid adoption of blood tests for Alzheimer's biomarkers was a central topic of discussion. Earlier this month, at the Alzheimer’s Association International Conference (AAIC), substantial interest was showcased with over 140 presentations primarily focusing on the NULISAseq CNS Disease 120, Neuro 220, and AD 5-plex panels, as well as the NULISAqpcr BD-pTau217 single plex assays, all of which incorporate ALZpath's proprietary technology.

Essentially, ALZpath, Inc. holds a commendable position at the forefront of diagnostic solutions for Alzheimer's disease, particularly through its pTau217 antibody, which plays a critical role in the latest blood tests available. This breakthrough is transforming the methods by which Alzheimer's disease is diagnosed, treated, and monitored. The organization leverages collaborations with premier laboratories and licensing agreements with influential industry players, thereby facilitating accurate and scalable testing solutions for clinicians and patients globally.

ALZpath’s relentless innovations and its contributions to the field have garnered various accolades such as Time Magazine's Best Inventions in 2024, Fast Company’s Most Innovative Companies in 2025, and the BioTech Breakthrough Award for “Diagnostic Innovation of the Year” in 2025. For further details about ALZpath and its groundbreaking work, interested parties can visit their official website at ALZpath and follow them on their social media platforms including LinkedIn, X, BlueSky, and Facebook.

In conclusion, this enhanced collaboration between ALZpath and Alamar Biosciences not only underscores the progress being made in Alzheimer's diagnostics but also reflects a collective commitment to improving patient outcomes through innovative medical technology.